Азерутамиг

Prop. INN (наименование, предложенное ВОЗ)

2920336-42-9

immunoglobulin (H-gamma1_L-kappa)_scFvkh-H-gamma1(h-CH2-CH3), anti-[Homo sapiens KLRK1 (killer cell lectin like receptor K1, NKG2D, KLR, NKG2-D, CD314)] and anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], Homo sapiens and humanized monoclonal antibody, bispecific;
H-gamma1 heavy chain Homo sapiens, anti-KLRK1 (1-451) [VH (Homo sapiens IGHV3-21*01 (100%) -(IGHD) -IGHJ5*02 (100%), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*01 G1m17,1 CH1 K120, CH3 D12, L14, G1v75 CH3 C5, G1v90 E16, W88 (CH1 K120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 Y5>C (354), D12 (361), L14 (363), K16>E (365), K88>W (414) (346-450), CHS K2>del (451)) (123-451)], (225-214')-disulfide with L-kappa light chain Homo sapiens, anti-KLRK1 (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (97.9%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')];
scFvkh-G1(h-CH2-CH3) heavy chain humanized, anti-ERBB2 (1''-475'') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (90.9%) Q120>C (100''), CDR-IMGT [6.3.9] (27''-32''.50''-52''.89''-97'')) (1''-107'') -20-mer tetrakis(tetraglycyl-seryl) linker (108''-127'') -VH (Homo sapiens IGHV3-66*01 (80.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (153''-160''.178''-185''.224''-236'')) (128''-247'') -2-mer alanyl-seryl linker (248''-249'') -Homo sapiens IGHG1*01 h-CH2-CH3 G1m1 CH3 D12, L14, G1v74 CH3 C10, G1v91 R3, V84.2, T85.1 (hinge 6-15 (250''-259''), CH2 (260''-369''), CH3 Q3>R (376''), S10>C (383''), D12 (385''), L14 (387''), D84.2>V (428''), F85.1>T (434'') (370''-474''), CHS K2>del (475'')) (250''-475'')]; dimer (231-255'': 234-258'':354-383'')-trisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

Поделиться этой страницей